Q3 2020 Sales Performance
bintrafusp alfa (M7824)*: a first-in-class TGF-ẞ/anti-PDL1 therapy
Unique design offers potential for superiority against the competitive landscape
gsk
The
target
The
agent
PD-L1 and TGF-ẞ are key pathways with independent and
complementary immunosuppressive functions
- Blocking TGF-ẞ signalling may sensitize tumours to anti-
PD-1/PD-L1 therapies and lead to synergistic and superior
anti-tumour activity compared with monotherapies
M7824 is a bifunctional fusion protein with dual function
designed to simultaneously block the anti-PD-1 and
anti-TGFB pathways
- Fully humanised protein immunoglobulin G1 (IgG1) mAb
against human PD-L1 fused to the extracellular domain of
human TGF-ẞ receptor II, which functions as a TGF-ẞ trap
Anti-PD-L1 moiety
Alliance with Merck KGaA, Darmstadt, Germany; # Salati et al., ASCO 2019; ^ Ueno et al., ESMO 2018
TGF-ẞ trap moiety
M7824 is an investigational bifunctional immunotherapeutic that combines
a TGF-B trap (yellow) with an antibody against PD-L1 (blue) in one fusion
protein. Targeting both pathways with M7824 aims to control tumor growth
by potentially restoring and enhancing anti-tumor responses.
53
3View entire presentation